Pre-clinical assessment of DRF 4367, a novel COX-2 inhibitor: Evaluation of pharmacokinetics, absolute oral bioavailability and metabolism in mice and comparative inter-species in vitro metabolism

References

• Chauret N, Yergey JA, Brideau C, Friesen RW, Mancini J, Riendeau D, Silva J, Styhler A, Trimble AS, Nicoll-Griffth DA. 2001. In vitro metabolism considerations, including activity testing of metabolites, in the discovery and selection of COX-2 inhibitor etoricoxib (MK-0663). Bioorganic Medicinal Chemistry Letters 11:1059–1062.
   PubMed Web of Science ®Google Scholar
• DeWitt LD. 1999. COX-2 selective inhibitors: The new super aspirins. Molecular Pharmacology 4:625–631.
   Google Scholar
• Gibaldi M, Perrier D. 1982. Pharmacokinetics. 2nd ed. New York: Dekker.
   Google Scholar
• Gierse JK, Hauser SD, Creely DP, Koboldt C, Rangwala SH, Isakson PC, Seibert K. 1995. Expression and selective inhibition of the constitutive and inducible forms of human cyclo-oxygenase. Biochemical Journal 305:479–484.
   PubMed Web of Science ®Google Scholar
• Gradolatto A, Canivenc-Lavier MC, Basly JP, Siess MH, Teyssier C. 2004. Metabolism of apigenin by rat liver phase I and phase II enzymes and by isolated perfused rat liver. Drug Metabolism and Disposition 32:58–65.
   PubMed Web of Science ®Google Scholar
• Graul A, Martel AM, Castaner RM. 1997. Celecoxib: Antiinflammatory cyclooxygenase inhibitor. Drugs of Future 22:711–714.
   Google Scholar
• Halpin RH, Geer LA, Zhang KE, Marks TM, Dean DC, Jones AN, Melillo D, Doss G, Vyas KP. 2000. The absorption, distribution, metabolism and excretion of rofecoxib, a potent and selective cyclooxygenase-2 inhibitor, in rats and dogs. Drug Metabolism and Disposition 28:1244–1254.
   PubMed Web of Science ®Google Scholar
• Halpin RA, Porras AG, Geer LA, Davis MR, Cui D, Doss GA, Woolf E, Musson D, Matthews C, Mazenko R, Schwartz JI, Lasseter KC, Vyas KP, Baillie TA. 2002. The disposition and metabolism of rofecoxib, a potent and selective cyclooxygenase-2 inhibitor, in human subjects. Drug Metabolism and Disposition 30:684–693.
   PubMed Web of Science ®Google Scholar
• Rao MNVS, Biju B, Ansar AK, Mujeeb S, Ramesh M, Srinivas NR 2003. Open access generic method for continuous determination of major human CYP 450 substrates/metabolites and its application in drug metabolism studies. Xenobiotica 12:1233–1245.
   Google Scholar
• Mamidi RNVS, Mullangi R, Kota J, Bhamidipati R, Khan AA, Katneni K, Dada S, Singh SK, Rao YK, Seshagiri Rao C, Srinivas NR, Rajagopalan R. 2002. Pharmacological and pharmacokinetic evaluation of celecoxib prodrugs in rats. Biopharmaceutics and Drug Disposition 23:273–282.
   PubMed Web of Science ®Google Scholar
• Mangold JB, Gu H, Rodriguez LC, Bonner J, Dickson J, Rordorf C. 2004. Pharmacokinetics and metabolism of lumiracoxib in healthy male subjects. Drug Metabolism and Disposition 32:566–571.
   PubMed Web of Science ®Google Scholar
• Paulson SK, Hribar JD, Liu NW, Hajdu E, Bible RH, Piergies A, Karim A. 2000a. Metabolism and excretion of [14C] celecoxib in healthy male volunteers. Drug Metabolism and Disposition 28:308–314.
   PubMed Web of Science ®Google Scholar
• Paulson SK, Zhang JY, Breau AP, Hribar JD, Liu NW, Jessen SM, Law YM, Cogburn JN, Gresk CJ, Markos CS, Maziasz TJ, Schoenhard GL, Burton EG. 2000b. Pharmacokinetics, tissue distribution, metabolism, and excretion of celecoxib in rats. Drug Metabolism and Disposition 28:514–521.
   PubMed Web of Science ®Google Scholar
• Ramesh M, Mamidi RNVS, Jaganath K, Singh SK, Rao YK, Seshagiri Rao C, Rajagopalan R, Srinivas NR. 2003. Oral bioavailability and pharmacokinetics of DRF 4367, a new cox-2 inhibitor in rats. European Journal of Drug Metabolism and Pharmacokinetics 28:137–141.
   PubMed Web of Science ®Google Scholar
• Ramesh M, Reddy RK, Ravikanth B, Mamidi RNVS, Srinivas NR. 2004. HPLC method for determination of DRF 4367 in rat plasma: Validation and its application to pharmacokinetics in Wistar rats. Biomedical Chromatography 18:576–580.
   PubMedGoogle Scholar
• Remmel RP, Crews BC, Kozak KR, Amit AS, Marnett U. 2004. Studies on the metabolism of the novel, selective cyclooxygenase-2 inhibitor indomethacin phenethylamide in rat, mouse, and human liver microsomes: Identification of active metabolites. Drug Metabolism and Disposition 32:113–122.
   PubMed Web of Science ®Google Scholar
• Riendeau D, Charleson S, Cromlish W, Mancini JA, Wong E, Guay J. 1997. Comparison of the cyclooxygenase-1 inhibitory properties of non-steroidal anti-inflammatory drug (NSAIDs) and selective COX-2 inhibitors, using sensitive microsomal and platelet assays. Canadian Journal of Physiology and Pharmacology 57:465–480.
   Google Scholar
• Rodrigues DA, Halpin RA, Geer LA, Cui D, Woolf EJ, Matthew CZ, Gottesdiener KM, Larson PJ, Lasseter KC, Agrawal GB. 2003. Absorption, metabolism, and excretion of etoricoxib, a potent and selective cyclooxygenase-2 inhibitor, in healthy male volunteers. Drug Metabolism and Disposition 31:224–232.
   PubMed Web of Science ®Google Scholar
• Singh SK, Ganapati Reddy P, Srinivasa Rao K, Lohray BB, Seshagiri Rao C, Misra P, Rajjak SA, Rao YK, Venkateswarlu A. 2004. Polar substitutions in the benzenesulfonamide ring of celecoxib afford a potent 1,5-diarylpyrazole class of COX-2 inhibitors. Bioorganic Medicinal Chemistry Letters 14:499–504.
   PubMed Web of Science ®Google Scholar
• Smith WL, DeWitt DL. 1996. Prostaglandin endoperoxide H synthases-1 and 2. Advance Immunology 62:67–215.
   Google Scholar
• Teyssier C, Siess MH. 2000. Metabolism of dipropyl disulfide by rat liver phase I and phase II enzymes and by isolated perfused rat liver. Drug Metabolism and Disposition 28:648–654.
   PubMed Web of Science ®Google Scholar
• Vane JR, Bakhle YS, Botting RM. 1998. Cyclooxygenase 1 and 2. Annual Reviews in Pharmacology and Toxicology 47:1151–1156.
   Google Scholar
• Yuan JJ, Yang DC, Zhang JY, Bible R, Karim A, Findlay JWA. 2002. Disposition of a specific cyclooxygenase-2 inhibitor, valdecoxib, in human. Drug Metabolism and Disposition 30:1013–1021.
   PubMed Web of Science ®Google Scholar
• Zhang JY, Yuan JJ, Wang YF, Bible RH, Breau AP. 2003. Pharmacokinetics and metabolism of a COX-2 inhibitor, valdecoxib, in mice. Drug Metabolism and Disposition 31:491–501.
   PubMed Web of Science ®Google Scholar